American Renal Associates Holdings, Inc (ARA): Price and Financial Metrics

American Renal Associates Holdings, Inc (ARA)

Today's Latest Price: $11.50 USD

0.01 (0.09%)

Updated Oct 23 7:00pm

Add ARA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 70 in Medical - Services

See all "A" rated Strong Buy stocks

ARA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ARA is -10.56 -- better than merely 1.6% of US stocks.
  • The price/operating cash flow metric for American Renal Associates Holdings Inc is higher than only 13.06% of stocks in our set with a positive cash flow.
  • ARA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.6% of US stocks.
  • If you're looking for stocks that are quantitatively similar to American Renal Associates Holdings Inc, a group of peers worth examining would be EAT, HOV, WOW, DVCR, and ENDP.
  • Visit ARA's SEC page to see the company's official filings. To visit the company's web site, go to

ARA Stock Price Chart Interactive Chart >

Price chart for ARA

ARA Price/Volume Stats

Current price $11.50 52-week high $11.98
Prev. close $11.49 52-week low $5.57
Day low $11.44 Volume 99,155
Day high $11.55 Avg. volume 110,013
50-day MA $8.15 Dividend yield N/A
200-day MA $7.51 Market Cap 397.99M

American Renal Associates Holdings, Inc (ARA) Company Bio

American Renal Associates provides outpatient dialysis services in the United States. The company focuses on joint venture relationships with nephrologists. It offers services to hospitals that include dialysis patient discharge coordination; and acute inpatient dialysis services, such as inpatient hemodialysis, inpatient peritoneal dialysis, C.V.V.H., C.R.R.T., and apheresis. The company was founded in 1999 and is based in Beverly, Massachusetts.

ARA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$11.50$28.27 148%

We started the process of determining a valid price forecast for American Renal Associates Holdings Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that American Renal Associates Holdings Inc ranked in the 66th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 148.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for American Renal Associates Holdings Inc ended up being:

  • 35% of the company's capital comes from equity, which is greater than merely 15.93% of stocks in our cash flow based forecasting set.
  • American Renal Associates Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 15. This value is greater than 94.84% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of American Renal Associates Holdings Inc? See PDEX, FTLF, GTS, FMS, and CHE.

ARA Latest News Stream

Event/Time News Detail
Loading, please wait...

ARA Latest Social Stream

Loading social stream, please wait...

View Full ARA Social Stream

Latest ARA News From Around the Web

Below are the latest news stories about American Renal Associates Holdings Inc that investors may wish to consider to help them evaluate ARA as an investment opportunity.

American Renal Associates +65% on acquisition by Nautic Partners for $853M

American Renal Associates (ARA) to be acquired by Innovative Renal Care, an affiliate of Nautic Partners in an all-cash transaction for an aggregate enterprise valuation of ~$853M.ARA shareholders will receive $11.50 per share in cash, representing an approximate premium of 66% from the last closing price.“I have decided to delay...

Seeking Alpha | October 2, 2020

American Renal Associates Holdings, Inc. 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by American Renal Associates Holdings, Inc. in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 10, 2020

Edited Transcript of ARA earnings conference call or presentation 12-May-20 1:00pm GMT

Q1 2020 American Renal Associates Holdings Inc Earnings Call

Yahoo | June 19, 2020

American Renal Associates (ARA) Upgraded to Buy: Here's What You Should Know

American Renal Associates (ARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research | May 22, 2020

American Renal Associates Holdings (ARA) Q1 2020 Earnings Call Transcript

Joining for today's presentation are Joe Carlucci, our chairman and CEO; Mark Herbers, our interim chief financial officer; and Dr. Also joining on the call today are Syed Kamal, our president; and Jillian Bernard, our controller.

Yahoo | May 12, 2020

Read More 'ARA' Stories Here

ARA Price Returns

1-mo 83.71%
3-mo 80.25%
6-mo 59.72%
1-year 46.50%
3-year -10.37%
5-year N/A
YTD 10.90%
2019 -9.98%
2018 -33.79%
2017 -18.23%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9309 seconds.